

## 2<sup>nd</sup> Canadian COVID-19 Immunology Meeting

Date: May 14th, 8:00am-10:00am PDT (11:00am-1:00pm EDT)

Contact: Brad Nelson, BC Cancer [bnelson@bccrc.ca](mailto:bnelson@bccrc.ca)

Time	Presenter	Title
8:00	<b>Brad Nelson, PhD</b> Immunotherapy Program, BC Cancer & UBC	Welcome
8:01	<b>Dr. Volker Gerdts</b> Director and CEO, VIDO-InterVac	COVID-19 vaccine research at VIDO-InterVac
8:20	<b>Dr. David Evans</b> Professor, Medical Microbiology & Immunology University of Alberta	Vaccinia virus-based Covid 19 vaccines
8:39	<b>Zhou Xing, MD, PhD</b> Professor, McMaster Immunology Research Centre Department of Pathology & Molecular Medicine McMaster University <b>Brian Lichty, PhD</b> Professor, McMaster Immunology Research Centre Department of Pathology & Molecular Medicine McMaster University	Development of an Ad-based aerosol vaccine strategy to target respiratory mucosal immunity against COVID-19
8:58	<b>Carolina Ilkow</b> Scientist/Assistant Professor, Ottawa Hospital Research Institute and University of Ottawa	Re-purposing oncolytic virus platforms to build an effective vaccine for SARS-CoV-2
9:17	<b>Shawn P. Kubli, PhD</b> Scientific Associate Laboratory of Dr Tak Mak Princess Margaret Cancer Centre	Landscape mapping the COVID-19 T cell response across diverse HLA through identification and characterization of epitopes and T cell receptors related to SARS-CoV-2
9:36	<b>Josef Penninger, MD</b> Director, Life Sciences Institute, University of British Columbia Professor, Department of Medical Genetics, University of British Columbia	ACE2 as a rational therapy for covid19
9:55	<b>Brad Nelson, PhD</b> Immunotherapy Program, BC Cancer, UVIC, UBC	Summary, next steps